Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 3/20 | 0.35 |
| ▸ | AHCY | P23526 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 4/20 | 0.31 |
| ▸ | RAB9A | P51151 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4232839 | 0.95 | ABCB1 (0.34) | ABCB1AHCYLMNA | |
| SCHEMBL4235987 | 0.94 | ABCB1 (0.40) | ABCB1AHCYMAPTOPRK1BRD4 | |
| SCHEMBL4237897 | 0.94 | ABCB1 (0.35) | ABCB1MAPK1 | |
| SCHEMBL4233287 | 0.93 | ABCB1 (0.36) | ABCB1AHCYMAPTOPRK1BRD4 | |
| SCHEMBL4237409 | 0.92 | MAPT (0.32) | MAPTRAB9ANPC1PKMOPRK1 | |
| SCHEMBL4564449 | 0.90 | AAK1 (0.32) | ABCB1OPRK1GNRHR | |
| SCHEMBL4236245 | 0.86 | ABCB1 (0.31) | ABCB1OPRK1GNRHR | |
| SCHEMBL4240638 | 0.86 | ACACB (0.32) | OPRK1LMNAMAPK1GNRHR | |
| SCHEMBL4229017 | 0.86 | ABCB1 (0.34) | ABCB1MAPTRAB9ANPC1OPRK1 | |
| SCHEMBL4231680 | 0.85 | ACACB (0.33) | OPRK1MAPK1GNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | TAKEDA CAMBRIDGE LIMITED (GB) | 2009-08-20 | — | — | US | disclosed |
| EP-1896465-A1 | HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS | Takeda Cambridge Limited (GB) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007000582-A1 | HETEROCYCLIC NON-PEPTIDE GNRH ANTAGONISTS | TAKEDA CAMBRIDGE LIMITED (GB) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209522-A1 | Heterocyclic Non-Peptide GNRH Antagonists | GNRHR, GHRHR, FSHR | ABCB1 4102/4885AHCY 2016/4885MAPT 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.